Biofortis, a clinical research organisation specialized in nutrition and microbiota analysis, has taken all the necessary steps regarding the health crisis related to COVID-19 by providing diagnostic tests, both virological and serological. Indeed, this type of public health mission therefore makes sense for Biofortis since it hosts a central laboratory for clinical studies.
In the COVID-19 chronology, the viral particles of SARS-CoV-2 are of course the first to be detectable, followed by the host’s antibodies. Virological tests can detect the presence of the coronavirus in infected individuals, while serological tests can be used to identify people who have been previously exposed to SARS-CoV-2 and developed antibodies against it.
By mobilising its resources and approaching the authorities, Biofortis supports the national fight against COVID-19 by offering its services of virological and serological testing.
As part of the national effort to deploy diagnostic tests, Biofortis has received an agreement to offer its analytical capacity to medical biology laboratories in order to meet the need for coronavirus test-detection of the SARS-CoV-2 genome by RT PCR. Biofortis is supporting Bioliance by strengthening its capacity to detect viral particles on swabs. In compliance with regulatory guidelines and for the safety of laboratory technicians, Biofortis is able to safely manage the analytical part of the diagnosis while the first stage of nasopharyngeal sampling and the last stage of biological interpretation are carried out by medical laboratories.
According to public health authorities, serological tests that detect antibodies against viral antigens have a place in epidemiological surveillance by identifying people who have been in contact with the SARS-CoV-2 virus, using a nucleic acid amplification technology.
During the phase of activity relaunch, it is important to reaffirm your commitment to protect employees’ health and provide reassurance to your staff. Thus, Biofortis can support you with the serological testing of your voluntary employees in order to identify people who have been already exposed to SARS-CoV-2 and developed antibodies against SARS-CoV-2 virus.This information can be used to reorganize teams according to the positions most exposed to the public.
Contact Biofortis for more information: firstname.lastname@example.org